Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of APTIOM (eslicarbazepine acetate) for Partial epilepsies in children younger than four years of age.

Trial Profile

A phase III trial of APTIOM (eslicarbazepine acetate) for Partial epilepsies in children younger than four years of age.

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Apr 2023 According to a Sumitomo Pharma media release, the Sumitomo Pharma USA companies (Sumitovant Biopharma, Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Sumitomo Pharma America Holdings, Sumitomo Pharma Oncology and Sunovion Pharmaceuticals) combined and named as Sumitomo Pharma America
    • 15 Mar 2017 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top